Clinical trials: Zoster
Varicella
Correlation of Protection Against Varicella in an Exploratory Study
This study consists of two parts. Part 1 is a retrospective cohort study and part 2 is a prospective cohort study. In Part 1 ,the scaled logit model was used to assess the correlation between varicella-zoster virus (VZV) antibody…
- Trial name
- NCT06482216
- Testing
- Varicella vaccine
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.
Herpes Zoster
Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older
The purpose of this study is to evaluate the persistence of immune response to the HZ vaccine as well as safety up to 10 years after the first dose of initial vaccination course.
- Trial name
- NCT02735915
- Testing
- Herpes Zoster Vaccine GSK1437173A
- Where
- 7 sites in Czechia, Germany and 1 more
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chickenpox
A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age
The purpose of this study is to evaluate the immune response and safety of GSKs investigational varicella vaccine (VNS Vaccine) compared to an already approved varicella vaccine, Varivax (VV), when administered as second dose to…
- Trial name
- NCT06806137
- Testing
- Investigational varicella vaccine, Marketed varicella vaccine, MMR vaccine
- Where
- 6 sites in Dominican Republic, Honduras
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Shingles, Herpes Zoster Infection
A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults
The purpose of this clinical study is to learn about the safety, extent of the side effects (reaction to vaccine), and immune response (your immune system's reaction) of the study vaccine called Varicella Zoster Virus modRNA (VZV…
- Conditions
- Shingles, Herpes Zoster Infection, Human
- Trial name
- NCT05703607
- Testing
- Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection, Candidate 1: PF-07915234: VZV modRNA Suspension for Injection, Candidate 2: PF-07921188: VZV modRNA Suspension for Injection
- Where
- 35 sites in United States
- Volunteers
- 484 people, healthy volunteers welcome
- Sponsor
- Pfizer
Herpes
A Phase I Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell)
To evaluate the safety and tolerability of different dosages of recombinant zoster vaccine (CHO cell) when administered to adults aged 40 years and older.
- Trial name
- NCT07633197
- Testing
- Recombinant Herpes Zoster Vaccine
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Chickenpox
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
The purpose of this study is to assess the consistency of immune response to three different lots of GSK's investigational varicella vaccine (VNS Vaccine), and to compare the safety and immune response of VNS vaccine to an…
- Trial name
- NCT06740630
- Testing
- Investigational varicella vaccine_Lot 1, Investigational varicella vaccine_Lot 2, Investigational varicella vaccine_Lot 3
- Where
- 97 sites in United States, Belgium and 9 more
- Volunteers
- 1,840 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chickenpox
Immune Persistence After Inoculated With One-dose Freeze-Dried Live Attenuated Varicella Vaccine in Children Vaccine in Children
The purpose of this study is to observe the persistence of protection, duration of protection, safety and breakthrough infection rates afforded by live attenuated varicella vaccine in children over a 5-year period.
- Trial name
- NCT01982409
- Testing
- Live Attenuated Varicella Vaccine
- Where
- China
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Changchun Changsheng Life Science and Technology Co., Ltd.
Measles, Mumps
V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)
The study is being conducted to demonstrate that V221 may be administered concomitantly with pneumococcal conjugate vaccine without impairing the safety or immunogenicity of measles, mumps, rubella, varicella, or the 7 serotypes…
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00109343
- Testing
- Comparator: ProQuad™ (V221), Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)
- Volunteers
- 1,027 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Measles, Mumps
Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes
This study will compare the immunogenicity and safety of the MeMuRu-OKA vaccine administered subcutaneously or using an alternative administration route.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00351923
- Testing
- MeMuRu-OKA (study vaccine)
- Where
- 20 sites in Germany
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Month 30 & 42 Extension Studies of CRD-004 Primary Study
The safety and immunogenicity of the GSK324332A vaccine has been evaluated up to Month 12 post-vaccination in the primary study.
- Trial name
- NCT00492648
- Testing
- Blood sampling for assay of persistence of immunogenicity
- Where
- Belgium
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Safety and Immunogenicity of SYS6017 in Healthy Participants Aged 40 Years or More
Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging.
- Trial name
- NCT06954818
- Testing
- A zoster mRNA vaccine SYS6017
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Prevention of : Herpes-Zoster
Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043)
Primary objective: Immunogenicity To demonstrate that a second dose of ZOSTAVAX® elicits higher varicella-zoster virus (VZV) antibody titres than a first dose of ZOSTAVAX® whether given as a 0-1 month schedule or as a 0-3 month…
- Trial name
- NCT00561080
- Testing
- Zostavax
- Volunteers
- 759 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Measles, Mumps
Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)
Primary objective: To compare if, when given concomitantly with VARIVAX® by the same route at 12-18 months of age using separate injection sites, a single dose of M-M-RTMII administered by IM route is as immunogenic as a single…
- Conditions
- Measles, Mumps, Varicella
- Trial name
- NCT00432523
- Testing
- M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX®
- Where
- 2 sites in France, Germany
- Volunteers
- 752 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Mumps, Rubella
Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
This is a study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals live attenuated measles-mumps-rubella-varicella vaccine given to healthy children in their second year of life.
- Conditions
- Mumps, Rubella, Measles, Varicella
- Trial name
- NCT00126997
- Testing
- Measles, Mumps, Rubella and Chickenpox (live vaccine)
- Where
- 54 sites in Finland, Germany and 2 more
- Volunteers
- 1,439 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above
The purposes of the study are to evaluate the immunogenicity and safety of different dose levels of recombinant herpes zoster vaccine (CHO Cells) with 2 doses at 2-month intervals in healthy subjects aged 30 years and older.
- Trial name
- NCT05856084
- Testing
- Low dose Recombinant Herpes Zoster Vaccine (CHO cells), High dose Recombinant Herpes Zoster Vaccine (CHO cells), Positive control
- Where
- China
- Volunteers
- 924 people, healthy volunteers welcome
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
Herpes Zoster
Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)
The study evaluated immunogenicity, safety, and tolerability of ZOSTAVAX™ Vaccine (V211) administered concomitantly versus nonconcomitantly with Quadrivalent Influenza Virus vaccine (inactivated) in participants ≥50 years of age.
- Trial name
- NCT02519855
- Testing
- ZOSTAVAX™, Influenza Vaccine
- Volunteers
- 882 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections
A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults
To assess the ability of RSVPreF3 OA investigational vaccine to generate an immune response when given in combination with HZ/su vaccine and its safety in older adults, aged >=50 years of age.
- Trial name
- RSV-OA=ADJ-020 (NCT05966090)
- Testing
- RSVPreF3 OA investigational vaccine, HZ/su vaccine
- Where
- 31 sites in United States, Canada
- Volunteers
- 530 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rubella, Varicella
Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine
Follow-up to evaluate the immunogenicity and safety of three production lots of GSK Biologicals' MMRV vaccine given as a two-dose schedule to healthy children in their second year of life, as compared to separate administration…
- Conditions
- Rubella, Varicella, Mumps, Measles
- Trial name
- NCT00406211
- Testing
- MMRV, MMR (Priorix®), Varicella (Varilrix®)
- Where
- 41 sites in Austria, Germany
- Volunteers
- 398 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles, Mumps
Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)
The purpose of this study is to demonstrate that an investigational refrigerated vaccine with measles, mumps, rubella, and varicella is well tolerated and has similar immune response when compared to a frozen vaccine with…
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00092430
- Testing
- V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster, Herpes Zoster Vaccine
Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
The purpose of this study is to assess the immunogenicity, reactogenicity and safety of the GSK Biologicals HZ/su candidate vaccine when its first dose is co-administered with Pneumovax 23™ vaccine in adults aged 50 years or…
- Trial name
- NCT02045836
- Testing
- Herpes Zoster vaccine GSK 1437173A, Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 865 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline